ASAN FOUNDATION
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1989-06-23
- Employees
- 501
- Market Cap
- -
- Website
- https://ails.amc.seoul.kr
Prospective Observation for Serial Changes in Acute Intracranial Artery Dissection Using HR-MRI
Not Applicable
Completed
- Conditions
- Cerebral ArteriesDissection
- Interventions
- Other: magnetic resonance imaging
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT03213470
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy
Phase 3
- Conditions
- Bladder CancerUreter CancerTransitional Cell Carcinoma
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 74
- Registration Number
- NCT03193788
- Locations
- 🇰🇷
Gil Medical Center, Incheon, Korea, Republic of
🇰🇷Dong-A University Medical Center, Pusan, Korea, Republic of
🇰🇷Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of
AMCPR (Augmented-Medication CardioPulmonary Resuscitation) Trial for OHCA
Phase 2
Completed
- Conditions
- Out-of-Hospital Cardiac Arrest
- Interventions
- Drug: VasopressinsDrug: Normal saline
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 110
- Registration Number
- NCT03191240
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Korea, Republic of
Development of Exercise Promotion Program Using a Mobile Community
Not Applicable
Completed
- Conditions
- Breast CancerPhysical Activity
- Interventions
- Device: Mobile community
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT03190720
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Korea, Republic of
Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC
Phase 2
Completed
- Conditions
- Advanced Rectal Cancer
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT03156036
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa, Korea, Republic of
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT03150706
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa, Korea, Republic of
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
Phase 2
- Conditions
- Cancer-associated ThrombosisEsophageal CancerStomach CancerDuodenal CancerEsophagogastric Junction CancerMalignant Gastrointestinal Stromal TumorAmpulla of Vater CancerHepatocellular CarcinomaPancreatic CancerBiliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 176
- Registration Number
- NCT03139487
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: [18F]THK-5351
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Asan Foundation
- Target Recruit Count
- 12
- Registration Number
- NCT03112096
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
Phase 2
Completed
- Conditions
- Biliary Tract CancerAdjuvant ChemotherapyCapecitabineGemcitabineCholangiocarcinomaCisplatin
- Interventions
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 101
- Registration Number
- NCT03079427
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Phase 2
Completed
- Conditions
- TemozolomideCapecitabineNeuroendocrine CarcinomaNeuroendocrine Tumors
- Interventions
- Drug: TEMCAP
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT03079440
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath